LU92915I2 - Ivermectine pour son usage dans le traitement de la rosacée - Google Patents

Ivermectine pour son usage dans le traitement de la rosacée Download PDF

Info

Publication number
LU92915I2
LU92915I2 LU92915C LU92915C LU92915I2 LU 92915 I2 LU92915 I2 LU 92915I2 LU 92915 C LU92915 C LU 92915C LU 92915 C LU92915 C LU 92915C LU 92915 I2 LU92915 I2 LU 92915I2
Authority
LU
Luxembourg
Prior art keywords
rosaceae
ivermectin
treatment
Prior art date
Application number
LU92915C
Other languages
English (en)
French (fr)
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92915(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of LU92915I2 publication Critical patent/LU92915I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
LU92915C 2003-04-24 2015-12-17 Ivermectine pour son usage dans le traitement de la rosacée LU92915I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US46899403P 2003-05-09 2003-05-09
PCT/EP2004/004950 WO2004093886A1 (en) 2003-04-24 2004-04-22 Topical formulation of ivermectin for the treatment of dermatological conditions

Publications (1)

Publication Number Publication Date
LU92915I2 true LU92915I2 (fr) 2016-02-17

Family

ID=33312271

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92915C LU92915I2 (fr) 2003-04-24 2015-12-17 Ivermectine pour son usage dans le traitement de la rosacée

Country Status (16)

Country Link
US (6) US7550440B2 (enExample)
EP (1) EP1620113B1 (enExample)
JP (2) JP5711867B2 (enExample)
KR (1) KR101187231B1 (enExample)
AU (1) AU2004231323C1 (enExample)
BR (1) BRPI0410503B8 (enExample)
CA (1) CA2522579C (enExample)
CY (2) CY1111797T1 (enExample)
FR (1) FR15C0069I2 (enExample)
HU (1) HUS1500048I1 (enExample)
LT (1) LTC1620113I2 (enExample)
LU (1) LU92915I2 (enExample)
MX (1) MXPA05011208A (enExample)
PL (2) PL1620113T3 (enExample)
RU (1) RU2350333C3 (enExample)
WO (1) WO2004093886A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1620113B1 (en) * 2003-04-24 2011-07-13 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
AU2003275509A1 (en) * 2003-05-25 2004-12-13 Eco Animal Health Ltd. Dimeticone-containing sustained formulation
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) * 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
WO2008067054A2 (en) 2006-10-12 2008-06-05 Topaz Pharmaceuticals Llc Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
ES2719200T3 (es) 2008-10-29 2019-07-09 Arbor Pharmaceuticals Llc Sistema conservante para formulaciones tópicas terapéuticas basadas en emulsión
JP2012513387A (ja) * 2008-12-23 2012-06-14 ガルデルマ・ソシエテ・アノニム 感水性の活性成分を含む、局所用医薬組成物
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN102872066B (zh) 2012-10-19 2014-07-02 厦门大学 伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9233118B2 (en) * 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
ES2836132T3 (es) 2013-08-08 2021-06-24 Novan Inc Composiciones tópicas y métodos de uso de las mismas
CN105916511A (zh) * 2013-11-29 2016-08-31 盖尔德玛公司 用于治疗和/或预防特应性皮炎的阿维菌素家族或美贝霉素家族的化合物
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016022066A1 (en) * 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
CA3000898A1 (en) * 2015-10-13 2017-04-20 Galderma Sa A process for preparing a stable emulsion comprising one or more avermectins
EP3362045B1 (en) 2015-10-13 2019-10-09 Galderma S.A. A process for preparing a composition comprising a high concentration of one or more avermectins
AU2017305853B2 (en) * 2016-08-04 2023-04-13 Galderma Holding SA Compositions and the use thereof for treating or preventing rosacea
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
WO2018083196A1 (en) 2016-11-03 2018-05-11 Nestlé Skin Health Sa Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
MX2019014772A (es) * 2017-06-12 2020-02-07 Lakewood Amedex Inc Formulaciones en gel de bisfosfocinas y usos de estas.
KR20200111177A (ko) 2017-12-15 2020-09-28 타르서스 파마수티칼스, 아이엔씨. 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법
KR20210019449A (ko) 2018-06-15 2021-02-22 더블유.알. 그레이스 앤드 캄파니-콘. 소포 활성제, 이의 제조 방법, 및 소포 제형
WO2020064843A1 (en) * 2018-09-28 2020-04-02 Galderma Research & Development Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso
US12161752B2 (en) 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
AU2020333860A1 (en) * 2019-08-21 2022-04-07 Leo Pharma A/S Solvent delivery system for topical delivery of active agents
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
MXPA01007486A (es) * 1999-01-25 2003-06-24 Optime Therapeutics Inc Formulaciones de liposomas.
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US20030064940A1 (en) * 2001-10-02 2003-04-03 Parks L. Dean Kit for treating acne vulgaris using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
US7064108B2 (en) * 2002-02-08 2006-06-20 Merck & Co., Inc. Topical ivermectin composition
CA2478589A1 (en) * 2002-03-04 2003-09-18 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
EP1620113B1 (en) * 2003-04-24 2011-07-13 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
DE602005020912D1 (de) * 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Also Published As

Publication number Publication date
US8598129B2 (en) 2013-12-03
CY2016031I1 (el) 2017-03-15
BRPI0410503B1 (pt) 2018-07-10
US8470788B2 (en) 2013-06-25
CA2522579A1 (en) 2004-11-04
FR15C0069I2 (fr) 2016-04-22
BRPI0410503B8 (pt) 2021-05-25
HUS1500048I1 (hu) 2017-10-30
JP5538461B2 (ja) 2014-07-02
CY2016031I2 (el) 2017-03-15
PL378932A1 (pl) 2006-06-12
JP2006524212A (ja) 2006-10-26
JP2012126738A (ja) 2012-07-05
EP1620113B1 (en) 2011-07-13
US20060100165A1 (en) 2006-05-11
CA2522579C (en) 2012-08-28
LTC1620113I2 (lt) 2018-02-26
JP5711867B2 (ja) 2015-05-07
AU2004231323C1 (en) 2016-11-03
KR101187231B1 (ko) 2012-10-02
FR15C0069I1 (enExample) 2015-12-04
MXPA05011208A (es) 2005-12-14
US8080530B2 (en) 2011-12-20
US7550440B2 (en) 2009-06-23
CY1111797T1 (el) 2015-10-07
RU2350333C2 (ru) 2009-03-27
KR20060004667A (ko) 2006-01-12
US20120077766A1 (en) 2012-03-29
US20120258062A1 (en) 2012-10-11
PL1620113T3 (pl) 2011-10-31
AU2004231323A1 (en) 2004-11-04
US20130209381A1 (en) 2013-08-15
RU2005136438A (ru) 2006-05-27
US20090252797A1 (en) 2009-10-08
RU2350333C3 (ru) 2018-08-24
AU2004231323B2 (en) 2009-12-10
US20090227668A1 (en) 2009-09-10
WO2004093886A1 (en) 2004-11-04
US8093219B2 (en) 2012-01-10
US8415311B2 (en) 2013-04-09
BRPI0410503A (pt) 2006-06-20
EP1620113A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
LU92915I2 (fr) Ivermectine pour son usage dans le traitement de la rosacée
EP1711191A4 (en) CHLORINE IN THE TREATMENT OF NEURODEEGENERATIVE DISEASES
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1636359A4 (en) PROCESS FOR PAIN TREATMENT
EP1755584A4 (en) Treatment of myopia
DK1506781T3 (da) Vaginalplejesammensætning
EP1765288A4 (en) METHOD FOR THE TREATMENT OF ENDOBRONCHIAL INFECTIONS
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY2015025I1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
EP1696877A4 (en) PROCESS FOR PAIN TREATMENT
EP2185202A4 (en) USE OF INTERLEUKIN-22 FOR THE TREATMENT OF FATTLEBER
DE60328797D1 (de) Blutbehandlungsgerät
DE602004015286D1 (de) Wäschebehandlungsmittel
EP1392818A4 (en) FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR
EP1830876A4 (en) TREATMENT OF SKIN METALS
EP1660009A4 (en) METHOD FOR TREATING ENDOMETRIOSIS
EP1776136A4 (en) TREATMENT OF DEMYELINISING DISEASES
EP1485109A4 (en) VASCULAR THERAPEUTICS
EP1838714A4 (en) METHOD FOR TREATING PAIN
DK1678085T3 (da) Fluidbehandlingsindretning
FR2887450B1 (fr) Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
DE60223576D1 (de) Hautbehandlungszusammensetzung
ATE399523T1 (de) Haarbehandlungszusammensetzung
EP1657311A4 (en) METHOD FOR EVALUATING AN OBJECT RELATING TO THE TREATMENT OF OBESITY
ATA13602003A (de) Therapeutisches behandlungsgerät